Related Experiment Video
Updated: Mar 10, 2026
Assessing the Innate Sensing of HIV-1 Infected CD4+ T Cells by Plasmacytoid Dendritic Cells Using an Ex vivo Co-culture System.
Published on: September 1, 2015
Idiopathic CD4 lymphocytopenia
Joel P Brooks1, Gisoo Ghaffari
11Department of Medical Education, Heart of Lancaster Regional Medical Center, Lititz, Pennsylvania, USA.
Insights
Idiopathic CD4 lymphocytopenia (ICL) is a rare condition causing low CD4 T-cells without a known cause. Patients often develop opportunistic infections, and current treatments show variable results.
Area of Science:
- Immunology
- Hematology
- Rare Diseases
Background:
- Idiopathic CD4 lymphocytopenia (ICL) is a rare disorder of unknown etiology.
- Diagnostic criteria include persistent CD4 T-cell lymphopenia without identified immune deficiencies.
- Characterized by CD4 T-cell counts below 300 cells/mL or 20% of total lymphocytes.
Observation:
- ICL patients are often diagnosed when complications arise, typically opportunistic infections.
- CD4 counts are frequently around 200 cells/mL at the time of diagnosis.
- The underlying T-cell defect in ICL differs from that in HIV, despite similar prophylactic treatments.
Findings:
- Literature review highlights clinical characteristics, diagnosis, and management of ICL.
- Current therapeutic strategies include IL-2, IFN-γ, IL-7, and stem cell transplantation, with inconsistent outcomes.
- ICL is a diagnosis of exclusion, requiring the absence of other causes for lymphopenia.
Implications:
- Increased awareness of ICL is crucial for timely diagnosis and appropriate management.
- Current prophylactic strategies, often mirroring HIV treatment, may not be optimally suited for ICL.
- Further research is needed to establish specific guidelines and effective treatments for ICL.
Background:
Idiopathic CD4 lymphocytopenia (ICL) is a rare disorder of unknown etiology. Diagnostic criteria include a persistent CD4 T-cell lymphopenia with no underlying primary or secondary immune deficiencies and a CD4 T-cell count of 300 cells/mL or 20% total lymphocyte on multiple occasions.
Objective:
To increase awareness of ICL and to provide a review of the clinical characteristics, diagnosis, and management of this disease process. Presently, many of these patients receive prophylactic treatment similar to other T-cell deficient conditions, most notably patients with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome; however, the same indications may not necessarily apply to this patient population because the T cells are not affected by a virus as in HIV.
Methods:
A literature search of salient articles that describe case reports and case series of ICL and their management were analyzed.
Results:
A case of ICL with a literature review is presented with emphasis on clinical pearls and pitfalls. The patients with ICL are usually identified with a CD4 count of 200 cells/mL when complications develop. Opportunistic infections are the most common initial manifestations. Current therapies used to increase CD4 levels include interleukin 2, interferon gamma, interleukin 7, and allogeneic hematopoietic stem cell transplantation, with variable results.
Conclusion:
ICL is a diagnosis of exclusion when there is no identifiable underlying cause for a low CD4 count. Although the nature of the T-cell problem is not the same in ICL and HIV, in the absence of specific guidelines, patients receive the same prophylactic treatment as patients with HIV.
More Related Videos
Related Concept Videos
01:25Immunodeficiency Diseases
There are three main causes of immunodeficiency...
01:22T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...